Detalhe da pesquisa
1.
Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective.
J Dermatolog Treat
; 33(2): 733-739, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-32432957
2.
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis.
Dermatol Ther (Heidelb)
; 10(1): 99-106, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31734937
3.
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
Dermatol Ther (Heidelb)
; 10(1): 133-150, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31749092
4.
Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.
Dermatol Ther (Heidelb)
; 9(4): 785-797, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-31630336